Join

Compare · HYPR vs MDT

HYPR vs MDT

Side-by-side comparison of Hyperfine Inc. (HYPR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HYPR and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • MDT is the larger of the two at $103.60B, about 740.1x HYPR ($140.0M).
  • Over the past year, HYPR is up 79.9% and MDT is down 7.8% - HYPR leads by 87.7 points.
  • MDT has been more active in the news (21 items in the past 4 weeks vs 11 for HYPR).
  • MDT has more recent analyst coverage (25 ratings vs 4 for HYPR).
PerformanceHYPR+79.90%MDT-7.80%
2025-06-09+0.00%2026-06-08
MetricHYPRMDT
Company
Hyperfine Inc.
Medtronic plc.
Price
$1.41+0.36%
$80.66-1.20%
Market cap
$140.0M
$103.60B
1M return
-16.86%
+3.49%
1Y return
+79.90%
-7.80%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
11
21
Recent ratings
4
25
HYPR

Hyperfine Inc.

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

MDT

Medtronic plc.

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Latest HYPR

Latest MDT